In the latest development, NurExone has developed two selective small inhibiting RNA sequences (siRNA) that target and inhibit proteins within the Peri-Neural Network (PNN) complex (Fig. 1A). The breakthrough sequences, detailed in a patent application held by the Company, are built upon a scientifically validated strategy for enhanced neuronal regeneration